Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
14.08. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
31.07. | Pasithea completes enrollment of first cohort in NF1 clinical trial | 4 | Investing.com | ||
31.07. | Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 402 | GlobeNewswire (Europe) | MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
11.07. | Pasithea Therapeutics terminiert Hauptversammlung für den 3. September 2025 | 2 | Investing.com Deutsch | ||
11.07. | Pasithea Therapeutics Corp. - 8-K, Current Report | 1 | SEC Filings | ||
20.06. | Pasithea Therapeutics Corp. - 8-K, Current Report | 2 | SEC Filings | ||
11.06. | Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board | 1 | GlobeNewswire (USA) | ||
02.06. | Pasithea reports promising phase 1 results for cancer drug | 1 | Investing.com | ||
02.06. | Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025 | 207 | GlobeNewswire (Europe) | -- PAS-004 demonstrates preliminary clinical activity as a monotherapy in patients with heavily pre-treated, refractory solid tumors -- -- One patient in cohort 4A (15mg capsule) with stage 4 BRAF-mutated... ► Artikel lesen | |
20.05. | Pasithea Announces Strong Preclinical Results For PAS-004 In Inflammatory Disease Model | - | RTTNews | ||
20.05. | Pasithea's PAS-004 shows promise in inflammatory disease study | 1 | Investing.com | ||
20.05. | PAS-004 von Pasithea zeigt vielversprechende Ergebnisse in Studie zu Entzündungskrankheiten | 1 | Investing.com Deutsch | ||
20.05. | Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases | 3 | GlobeNewswire (USA) | ||
15.05. | Pasithea Therapeutics Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
14.05. | Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site | 190 | GlobeNewswire (Europe) | -- First patient expected to be dosed during Q2 2025 ---- Trial will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy in both plexiform neurofibromas and... ► Artikel lesen | |
07.05. | Pasithea Therapeutics Corp. - 8-K, Current Report | 3 | SEC Filings | ||
07.05. | Pasithea Therapeutics Announces Closing of $5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
06.05. | Pasithea Therapeutics Announces Pricing of $5 Million Public Offering | 4 | GlobeNewswire (USA) | ||
06.05. | Pre-market Movers: Marin Software, Pasithea Therapeutics, China SXT Pharmaceuticals, Tactile Systems Technology, ThredUp | 568 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 09.00 A.M. ET).In the Green Marin Software Incorporated (MRIN) is up over 141%... ► Artikel lesen | |
06.05. | Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results | 5 | Benzinga.com |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
OCUGEN | 0,860 | -0,53 % | Ocugen - Novel cell therapies for retinal diseases | Ocugen's modifier gene therapy (MGT) platform is designed to regulate gene expression to restore visual function across both genetically diverse inherited retinal diseases (IRDs) and retinal conditions... ► Artikel lesen | |
GENPREX | 1,820 | -100,00 % | Genprex, Inc.: Genprex Issues Stockholder Letter and Provides 2025 Corporate Update | Company Achieves Multiple Clinical Development Milestones in 2025
Patient Treatment Continues in Two Lung Cancer Clinical Trials
AUSTIN, Texas, Aug. 4, 2025 ... ► Artikel lesen | |
QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
ARRIVENT BIOPHARMA | 19,120 | -0,52 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today |